Institute of Metagenomics and Microbial Technologies (IMMT) is committed to make new compounds from bacterial communities in nature, like enzymes. The focus of IMMT is to develop customised solutions for our clients specific problems. The solutions are based on novel bioactive natural compounds produced by microbes for successful medical and industrial applications.
IMMT is build on its founders wide experiences in analyzing the functioning of microbial communities in the last 15 years. By working on over 40 research and industrial projects, they have developed proprietary technologies for the extraction and processing of information of the DNA/RNA from bacteria present in native environments.
We look forward to bring diversity into your industrial and manufacturing processes and make your products more efficient. Please contact us by E: firstname.lastname@example.org or T: +386 (0)41 966 665.
Cooperating for 5 years
Ales Lapanje, PhD
Tomaz Rijavec, PhD
Jan Zrimec, PhD
Driven by the belief that our team at the Institute of Metagenomics and Microbial Technologies (IMMT) can make a great contribution to global health and wellbeing, we put all our knowledge, effort and time into obtaining new compounds from bacterial communities in nature, like enzymes.
Our solution enables over 6 orders of magnitude higher probability to get something new and bioactive. It uses application directed approach to obtain new molecules from information coded in the DNA/RNA molecules from bacteria present in native environments. This approach allows the highest probability to obtain new bioactive compounds needed for successful medical and industrial applications.
Our founders can make this possible due to their strong fundamental knowledge and experience in the functioning of microbial communities which was gained in 15 years of scientific and applicative research.
At the moment we are looking for strategic partners and investors to help us realize our vision of creating a novel platform for new, natural bioactive compounds.
The Institute of Metagenomics and Microbial Technologies (IMMT) receives funding to develop new bioactive compounds.
The Slovene Enterprise Fund has recently granted 42.000,00 EUR to IMMT to commercialize its platform for development of new bioactive compounds. The platform can be used in medicine, nutrition and environmental technologies. The investment was co-financed by the Republic of Slovenia and the European Union under the European Regional Development Fund.
Name of the operation: Commercialization of the technology platform for the development of new bioactive compounds for the use in biotechnology applications.
Link to the website of the European Cohesion Policy in Slovenia: www.eu-skladi.si
Institute of Metagenomics and Microbial Technologies Ltd. (IMMT)
SI - 1000 Ljubljana, Europe
Blaz Petric, CEO
Tel.: +386 (0)41 966 665